The most common side effects include headaches and flushing. Hims Hard Mints offers a chewable ED treatment that’s easy to use, stores in a discreet mint tin, and features a refreshing ...

Today’s rally breaks the stock into new-high territory in a clear move by investors to start buying HIM stock ahead of its next quarterly report on March 3. The move is also being fueled by a positive ...

Telehealth provider will make its big game debut as the semaglutide shortage continues to sustain the firm’s lower-priced ...

Hims & Hers, a tele-health start-up, aims to stand apart from dozens of Super Bowl commercials hawking snacks with a spot ...

Motivated is designed to offer convenient, private, and effective ED treatment that is more accessible. Providing FDA-approved medications and expert medical support from the comfort and privacy ...

The tele­health start­up Hims & Hers comes out swing­ing against phar­ma­ceu­ti­cal com­pa­nies in a provoca­tive new ad slat­ed to air dur­ing the Su­per Bowl. … ...

A Super Bowl ad for weight loss medications from telehealth company Hims & Hers is optimized to engage and infuriate ...

Hims & Hers Health, Inc ... across specialties and elevate the number of multi-condition personalized treatments, the number of multi-condition subscribers will continue to increase.

Telehealth company Hims & Hers is playing offense in a new ... the company’s weight loss program includes doctor-designed treatment plans to go along with obesity medications, concluding ...

1 Day HIMS -1.17% DJIA 0.65% S&P 500 -1.46% Retail/Wholesale -0.70% ...

I anticipate the FDA will soon declare the semaglutide shortage resolved, potentially slowing Hims' revenue growth ... an extension of their GLP-1 treatments using a rare FDA compound exemption.